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 ABSTRACT 
 Fanconi Anemia (FA) is a rare genetic disease caused by biallelic mutations in 
one of sixteen genes involved in the FA-BRCA DNA damage repair pathway. The 
proteins encoded by these genes function cooperatively in a common pathway which 
resolves lesions caused by interstrand crosslinks (ICLs). A critical step in this pathway 
is the monoubiquitination and chromatin targeting of FANCD2 and FANCI. The 
mechanism by which these proteins are targeted to chromatin is not understood. 
FANCD2 is known to interact with several downstream proteins while associated with 
chromatin. Finding new FANCD2 interacting proteins is critical to understanding how 
FANCD2 functions and how it is regulated within the cell. I have identified several 
candidate interacting proteins by immunoprecipitations (IPs) coupled with mass 
spectrometry. Candidates include transcription factors, chromatin remodeling complex 
components and proteins involved in chromosome maintenance and stability. These 
interactions are being validated and functionally characterized using a variety of 
techniques.  
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STATEMENT OF THE PROBLEM 
 
 FANCD2 is a critical protein in the FA pathway, which is monoubiquitinated 
by the core complex and localized to chromatin. Abrogation of either of 
monoubiquitination or chromatin localization results in the defective repair of damage 
caused by interstrand crosslinks. Both the regulation and function of FANCD2 are 
poorly understood. Identification of novel FANCD2 interacting proteins is critical to 
fully understanding the role that FANCD2 plays in the cell. The goal of the project is 
to identify novel FANCD2 interaction protein candidates using immunoprecipitation 
in tandem with mass spectrometry and then to validate and functionally characterize 
these interactions. The hope is that this data may shed light on the biochemical process 
in the cell and open new opportunities for patient treatment. 
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CHAPTER 1 
 
INTRODUCTION 
 
Fanconi Anemia 
Fanconi anemia is a rare genetic disease characterized by congenital defects, 
genomic instability, and a predisposition to bone marrow failure and cancer (Walden 
2014). Biallelic mutations in one of sixteen bona fide FA genes cause this disease. 
These gene products act cooperatively in the FA-BRCA pathway to recognize and 
repair ICLs within the DNA (Walden 2014). ICLs are highly genotoxic complex 
lesions which prevent DNA strand separation required for both replication and 
transcription (Deans 2011). The inability to correctly repair these lesions may lead to 
replication fork stalling or arrest, deleterious repair, or cell death particularly in white 
blood cells (Deans 2011). Most FA patients present anemia and early onset of bone 
marrow failure. Hypersensitivity to DNA crosslinking agents is a hallmark of FA 
patient cells (Kim 2012). This combination of increased propensity for hematological 
abnormalities and cancers, with fewer effective treatment options, makes the 
understanding of the molecular pathology critical for development of new treatment 
opportunities.   
 
FA Activation 
Much work has been done in recent years to help elucidate the mechanistic 
action of the FA proteins. The recognition and stabilization of the lesion is 
accomplished by FANCM, FAAP24, MHF1, and MHF2, which prevent replication 
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fork collapse (Meetei 2005, Ciccia 2007, Zhijiang 2010). Following lesion recognition 
the core complex is recruited which is composed of FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCF, FANCG, FANCL, and FANCM. The core complex 
monoubiquitinates FANCD2 and FANCI on K561 and K523 respectivly, which leads 
to chromatin targeting and the recruitment of downstream DNA repair proteins 
(Garcia-Higuera 2001, Sims 2007, Smogorzewska 2007). The monoubiquitination is 
seen as a marker of pathway activation. The loss of any core complex member, other 
than FANCM, abolishes FANCD2 and FANCI ubiquitination (Bakker 2009).  
 
FANCD2 
  FANCD2 is an orphan protein which has until recently been largely 
uncharacterized. The closest protein to FANCD2 is its paralog FANCI, which together 
form a heterodimer known as the ID2 complex. FANCD2 has four recognized 
domains, the EDGE, PIP, CUE, and NLS domains (Montes de Oca 2005, Howlett 
2009, Rego 2012, Boisvert 2013). FANCD2 has also been implicated in binding 
directly to chromatin though the mechanism for this remains unknown. Different 
forms of DNA, such as circular dsDNA, dsDNA, fragments and, ssDNA, have been 
shown to specifically increase the association between chromatin and FANCD2 
(Sareen 2012). It has also been proposed that FANCD2 harbors both nucleosome 
chaperone activity and the ability to promote site-specific transcriptional activation 
(Sato 2012, Park 2013). Despite these domains being characterized the functional and 
mechanistic role of this protein is still largely unknown. 
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FANCD2 Monoubiquitination 
 The monoubiquitination of FANCD2 and FANCI has been used as a marker 
for activation of the FA-BRCA pathway. The monoubiquitination event is key for the 
recruitment of FANCD2 and FANCI to chromatin. FANCD2 mutants that harbor a 
K561R mutation are not able to become ubiquitinated and do not rescue sensitivity to 
crosslinking agents (Garcia-Higuera 2001). The primary function of the FA core 
complex is this ubiquitination reaction. The ubiquitination is mediated through the E3 
ligase activity of FANCL and UBE2T, an E2 ubiquitin conjugating enzyme specific 
for FANCL (Meetei 2003, Machida 2006). This ubiquitination is easily measurable by 
western blotting as the ubiquitin conjugation causes a detectable shift in the masses of 
FANCD2 and FANCI. FANCB, FANCL and FAAP100 have been shown to form a 
subcomplex which is able to ubiquitinate FANCD2 in vitro indicating that the other 
core complex members have some other unknown functions which are required for 
efficient ubiquitination in vivo (Rajendra 2014). This ubiquitination conjugation is a 
reversible reaction using the deubiquitinating enzymes USP1 and UAF1 (Nijman 
2005, Cohn 2007).  
 
FA and DNA Repair 
 The monoubiquitination event of FANCD2 and FANCI leads to the eventual 
recruitment of downstream repair proteins. The downstream proteins consist of 
FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, 
FANCP/SLX4, and FANCQ/XPF. It was originally thought that FANCP/SLX4 and 
FAN1 were recruited to the sites of damage through a specific interaction with 
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ubiquitinated FANCD2, however it is now known that the nucleases are recruited 
through a mechanism independent of FANCD2 monoubiquitination (Kimiyo 2011, 
Kim 2011, Shereda 2010, Chaudhury 2014, Lachaud 2014). FANCP/SLX4 acts as a 
recruitment platform for the nuclease complexes XPF-ERCC1, MUS81-EME1 as well 
as SLX1, which are able to contribute to resolving the complex structure generated by 
the ICLs (Zhang 2014). The incisions created by the nucleases are critical for crosslink 
unhooking and enabling initiation of translesion synthesis (TLS) as well as double 
strand breaks (DSBs) formation (Walden 2014). 
 
TLS and Homologous Recombination 
 Once the crosslink has been unhooked TLS polymerases are recruited to the 
site to bypass the lesion. The TLS polymerases are able to synthesize across the lesion 
and allow for resumption of normal replication (Sharma 2013). FANCC has been 
shown to promote the recruitment of factors involved in switching to the error prone 
TLS replicative mechanism (Niedzwiedz 2004). Once the ICL lesion has been 
synthesized over by TLS, the DSBs that were created during nucleotide excision must 
be repaired in an error free manner to avoid the loss of genetic material and an 
increase in genomic instability. The remaining downstream proteins in the FA-BRCA 
pathway FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, and FANCO/RAD51C 
promote RAD51 loading onto single stranded DNA. RAD51 is critical to the 
homologous recombination (HR) pathway by its ability to coordinate with a 
homologous DNA sequence and promote strand invasion (Mazón 2010). This process 
prevents the loss of genetic information by using the paired strand as a template for the 
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damaged strand ensuring accurate hybridization across the previously damaged region. 
FA patients are thought to have difficulty in promoting HR over nonhomologous end 
joining (NHEJ) repair which, in contrast, is an error prone mechanism. The 
deregulation of this error prone repair pathway has been implicated as a possible cause 
for the genomic instability found in FA patients (Adamo 2010, Pace 2010, Bunting 
2010). It is important for patient treatment that both the mechanics and regulation of 
the FA-BRCA pathway are well understood. 
 
Unbiased Screening for FANCD2 Interactors 
 The discovery of novel FANCD2-interacting proteins is essential for a more 
complete understanding of the role that FANCD2 plays in the cell. Using a variety of 
methods FANCD2 has been shown to interact with several proteins including, but not 
limited to, FANCI, FANCE, FANCJ/BRIP1, MEN1, CtIP, and the MCM helicase 
proteins (Sims 2007, Smogorzewska 2007, Pace 2002, Gordon 2003, Chen 2014, Jin 
2003, Murina 2014, Unno 2014, Lossaint 2013). Biochemical based studies have 
resulted in a huge increase of the understanding in how FA works. The first six FA 
genes were identified through a positional cloning approach (Lo Ten Foe 1996, 
Fanconi anaemia/Breast cancer consortium 1996, Strathdee 1992, Timmers 2001, de 
Winter 1998, de Winter and Rooimans 2000, de Winter and Léveillé 2000). 
Biochemical approaches such as co-immunoprecipitations (co-IPs) have been 
instrumental in the discovery of the ten most recently discovered FA genes as well as 
several interacting partners (Meetei 2004, Howlett 2002, Dorsman 2007, Levran 2005, 
Litman 2005, Levitus 2005, Meetei 2003, Meetei 2005, Xia 2007, Reid 2007, Vaz 
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2010, Stoepker 2011, Bogliolo 2013). Identifying interacting networks and partners 
such as BRCA and BLM has provided a great deal of understanding about how the 
FA-BRCA pathway functions and what it is responsible for within the cell (Howlett 
2002, Pichierri 2004). Immunoprecipitation coupled with mass spectrometry is a 
proven technique within the FA field, contributing directly to the discovery of 
FANCN/PALB2 (Xia 2006). Similar techniques were recently used to identify the 
interaction between FANCD2 and the MCM helicases (Lossaint 2013). Using large 
scale systems combined with the sensitivity of modern biochemical techniques we 
hope to discover novel FANCD2 interacting proteins using an unbiased system.   
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CHAPTER 2 
 
METHODOLOGY 
 
Cell Culture 
HeLa cells (human cervical cancer cells, Scherer 1953) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco11965-092) supplemented with 
12% fetal bovine serum (FBS, Gibco 26140-079) 2 mM L-glutamine (Gibco 25030-
081) 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063). PD20 
(FA-D2 patient fibroblasts) cells were purchased from Coriell Cell Repositories 
(Catalog ID GM16633).  
PD20 cells are a human transformed cell line that have a heterozygous 
FANCD2 deficiency as a result of biallelic mutations and lack functional FANCD2. 
The maternal allele contains a frameshift mutation resulting in a severe truncation, and 
the paternal allele has a missense mutation, causing the cells to express highly 
diminished amounts of FANCD2 protein which fail to correct ICL sensitivity 
(Timmers 2001). The corrected cells we generated using pLenti6.2-FANCD2 and 
pDEST40-FANCD2-V5-6xHis. The pLenti6.2 construct incorporates a V5 epitope tag 
on the protein which can be targeted by commercially available antibodies and a 
blasticidin resistance so that cells can be cultured in media supplemented with 2µg/mL 
blasticidin (Invitrogen R210-01) for selection. The control lines have a stably 
incorporated pLenti6.2-LacZ-V5 cultured with 2µg/mL blasticidin (Invitrogen R210-
01) or, empty pMMP plasmid and is cultured in media supplemented with 1 µg/mL 
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puromycin (Sigma Aldrich P-8833). PD20s were grown in DMEM (Gibco11965-092) 
supplemented with 15% FBS (Gibco 26140-079) 2 mM L-glutamine (Gibco 25030-
081) 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063).  
MCF10A (nonmalignant epithelial cells, Cohet 2010) cells containing 
doxycycline inducible SMARCA2/BRM, SMARCA4/BRG1 (members of the 
SWI/SNF complex) and scrambled shRNA cassettes were a generous gift from 
Anthony Imbalzano, and Jeffrey Nickerson with help from Karen Imbalzano, and 
Jason Dobson. MCF10A cells were cultured in Dulbecco’s modified Eagle’s 
medium/nutrient mixture F-12 (DMEM/F-12, Gibco 11330-032) supplemented with 
5% horse serum (Gibco 16050-122), 100 mg/mL human epidermal growth factor 
(EGF, Peprotech AF-100-15), 1 mg/mL hydrocortizone (Sigma Aldrich H-0888), 1 
mg/mL cholera toxin (Sigma Aldrich C-8052), 10 mg/mL insulin (Sigma Aldrich I-
1882), 500 units/mL penicillin, and 500 µg/mL streptomycin (Gibco 15070-063). 
Induction of shRNA expression was achieved by treating with 0.01µg/mL of 
doxycycline (Sigma Aldrich D-9891) for 72 hours and confirmed by GFP expression.  
Cells were cultured at 37oC with 5% CO2 and subjected to 0.05% trypsin 
EDTA dissociation solution (Gibco 25300-054) for maintenance. Cells were treated 
with mitomycin C (MMC, Sigma Aldrich M-0503) to induce crosslink formation.  
 
Cellular Fractionation 
 Cells underwent a subcellular fractionation to enrich for chromatin associated 
proteins. Following treatment, cells were collected in 0.05% trypsin EDTA 
dissociation solution and DMEM, and pelleted in a centrifuge at 1200xg at 4oC over 4 
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minutes.  The pellet was resuspended and washed in phosphate buffered saline pH 7.4 
(Gibco 10010-023) and pelleted again. Cells were first lysed in ice cold cytoskeletal 
(CSK) buffer (10 mM PIPES pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 
1 mM EGTA, and 0.5% v/v Triton-X-100) for 10 minutes at 4oC. The remaining pellet 
was washed once with CSK buffer and subjected to either nuclease reaction buffer 
(NRB) (20 mM Tris HCl, 100 mM KCl, 2 mM MgCl2, 1mM CaCl2, 0.3M Sucrose, 
0.1% v/v Triton-X-100, Roche protease inhibitor cocktail tablet) or ice cold ATM 
lysis buffer (Sun 2009) (20 mM HEPES pH 7.4, 150 mM NaCl, .2% Tween20, 1.5 
mM MgCl, 1 mM EGTA, 2 mM DTT, 50 mM NaF, 500 µM Na3O4V, 1 mM PMSF, 
Roche protease inhibitor cocktail tablet). The sample was subjected to sonication for 
ten seconds at 10% amplitude using a Fisher Scientific Model 500 Ultrasonic 
Dismembrator then supplemented with 0.1% v/v micrococcal nuclease (New England 
Biolabs M0247S) for twenty minutes at room temperature or 0.05% v/v benzonase 
(Sigma Aldrich E-1014) for thirty minutes on ice, respectively. Samples were spun at 
16100xg for two minutes and the supernate containing the chromatin associated 
proteins were placed in a new ice cold tube. Chromatin fractions were quantified using 
the bicinchoninic acid (BCA) assay (PI-23227, Fisher) to allow for normalization. 
 
Antibodies 
 Mouse monoclonal antibodies used were α-tubulin (MS-581-P1, NeoMarkers), 
FANCD2 (sc-20022, Santa Cruz), GFP (sc-9996, Santa Cruz), H4 (L64C1, Cell 
Signaling), and V5 (R960-25, Invitrogen). 
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 Rabbit polyclonal antibodies used were CAPD2 (A300-601A, Bethyl), CAPD3 
(A300-604A, Bethyl), FANCD2 (NB100-182, Novus Biologicals), H2A (07-146, 
upstate), H3 (ab1791, Abcam), SMC1A (A300-055A, Bethyl), SMC4 (A300-064A, 
Bethyl), SMC6 (A300-237A, Bethyl), and VCP (ab109240, Abcam). 
 
Immunoprecipitation 
  FANCD2 immunoprecipitations were performed with protein G Sepharose 
(17-6002-35, GE) or protein G Dynabeads (10003D, Invitrogen). Beads were washed 
three times for 5 min in NETN100 (20 mM Tris-HCl, 100mM NaCl, 1 mM EDTA, 
1mM Na3O4V, 1 mM NaF, Roche protease inhibitor cocktail tablet) + 1% bovine 
serum albumin (BSA) (BP1600-100, Fisher) then once more for 15 min to block the 
beads. The beads are washed three times in NETN100 buffer. NETN100 is added to 
the chromatin fraction to q.s. the volume up to 1 mL. A portion of the pre-blocked 
beads are added to the mixture containing the nuclear fraction for thirty minutes while 
nutating at 4oC, to pre-clear any nonspecific interactions from the mixture. Using 
gentle centrifugation (or a magnet for Dynabeads) allows the beads to be separated 
from the mixture which is removed and placed into a new tube where the FANCD2 
antibody is added and allowed to incubate while nutating at 4oC. The beads are added 
to the reaction and allowed to incubate for an additional two hours while nutating at 
4oC. Gentle centrifugation (or the magnet) is used to sequester the beads at the bottom 
of the tube while the unbound supernatent components are aspirated. The beads are 
washed four times in NETN100. The beads are eluted with 2x LDS (NP-0008, 
NuPage) with 5% v/v β-mercaptoethanol with heating at 95oC for 10 min. 
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V5 Agarose Immunoprecipitation 
V5 immunoprecipitations were performed with V5 conjugated agarose beads 
(ab1229, Abcam). Beads were washed three times for five minutes in NETN100 (20 
mM Tris-HCl, 100mM NaCl, 1 mM EDTA, 1mM Na3O4V, 1 mM NaF, Roche 
protease inhibitor cocktail tablet) + 1% bovine serum albumin (BSA) (BP1600-100, 
Fisher) than once more for fifteen minutes to block the beads. The beads are than 
washed three times in NETN100 buffer. Samples were brought up to an equal volume 
using the ATM lysis buffer. V5 conjugated beads were added and allowed to incubate 
for two hours at 4oC while nutating. Beads were separated from the supernatant by 
gentle centrifugation. The supernatant was aspirated and the beads were washed four 
times with ice cold NETN100 for five minutes. After the final wash the beads were 
aspirated dry using a needle. The beads are eluted into 2x LDS (NP-0008, NuPage) 
with 5% β-mercaptoethanol by heating at 95oC for fifteen minutes. 
 
SDS-PAGE 
 Electrophoresis was accomplished using NuPAGE 3-8% Tris-Acetate and 4-
12% Bis-Tris polyacrylamide gels (EA0378BOX and NP0335BOX, NuPAGE). 
Samples were lysed by either CSK buffer, NRB, ATM lysis buffer or in 2% SDS lysis 
buffer (SDS) (2% v/v SDS, 50 mM Tris-HCl pH 7.4, 10 mM EDTA). Lysates were 
supplemented with 4x LDS (NP-0008, NuPage) to a 1x concentration except for IP 
eluates which were run in their 2x elution buffer. Samples were run with the 
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Kaleidoscope prestained standard (161-0324, Bio-Rad) for reference as a molecular 
weight marker.  
 
Immunoblotting 
 For immunoblotting analysis proteins were transferred from the SDS-PAGE 
matrix onto 0.45µm  polyvinylidene difluoride (PVDF) (IPVH00010, Immobilon) 
membrane with a semi-dry electrophoretic transfer cell (170-3940, Bio-Rad). Transfer 
membranes were rinsed in Tris-buffered saline with Tween 20 (TBST; 0.1% v/v 
Tween 20, 150 mM NaCl, 25 mM Tris-HCl, pH 7.6) and subsequently blocked in 5% 
w/v dry milk in TBST for one hour at room temperature. Membranes were repeatedly 
washed in TBST before being incubated with the primary antibody in TBST overnight 
at 4oC or for two hours at room temperature. Horseradish peroxidase conjugated 
secondary antibodies against mouse and rabbit IgG (NA931V and NA934V, GE) were 
hybridized to the primary antibodies. The complex was detected with 
chemiluminescent reagent (170-5060, Bio-Rad or NEL 101, NEL102, Perkin Elmer) 
and visualized using a film developer (CP1000, Agfa). 
 
Gel Staining, Tryptic Digestion and Mass Spectrometry 
 The SDS-PAGE matrix was stained using SimblyBlue SafeStain (LC6060, 
Invitrogen) or mass spec compatible silver stain (24600, Thermo). Staining was 
performed as described in the respective protocols. Tryptic digestion was performed 
using the in-gel tryptic digestion kit (89871, Thermo). Protocol was performed as 
described in the manual using TCEP for reduction and Iodoacetamide for alkylation. 
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When possible, digestion was performed inside a biosafety cabinet to reduce the 
prevalence of keratin contamination. Tryptic digestion was incubated at 30oC 
overnight. The supernate was removed and placed into a clean new tube. The 
remaining gel pieces were subjected to a secondary extraction using 50% acetonitrile 
and 5% formic acid. The secondary extraction was collected and combined with the 
primary extraction than stored in the -20oC freezer. Samples were submitted to Dr. 
James Clifton at Brown University EPSCoR proteomics facility. Samples were 
submitted as low complexity samples to be run through LC coupled MS/MS on the 
LTQ Orbitrap Velos mass spectrometer. 
 
Spectral Analysis 
 Analysis of spectral data was performed in multiple iterations using different 
systems. Initial analysis was performed using the MASCOT database which uses a 
probability based peptide finger printing method to automatically identify and evaluate 
spectral data (Perkins 1999). ProteoIQ v2.2 was used to remove hits that fell below the 
5% protein false discover rate threshold. ProteoIQ was used in tandem with manual 
curation of the raw MASCOT data to find samples that were differentially detected in 
the experimental and control samples. Exclusions were made based on relative 
abundance in the control samples, repositories of known contaminants, and subcellular 
location, as a result of the prerequisite fractionation (Mellacheruvu 2013). Manual 
curation relied heavily on the UniProt database though several cases required rigorous 
searches of the literature to determine protein function, possible validity, and 
relevance (Apweiler 2004).  
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CHAPTER 3 
 
RESULTS 
 
FANCD2 Interacting Proteins can be Detected by Mass Spectrometry. 
To determine if the system was workable, several pulldowns were performed 
to enrich for FANCD2 immune complexes.  Using a commercially available V5 
antibody it was possible to enrich for both FANCD2 and monoubiquitinated FANCD2 
(Figure 1). The remaining eluate from the immunoprecipitation did not present a 
differential banding pattern when stained (Figure 2). Lack of visual detection does not 
preclude detectable differences between samples, so gel pieces from the SDS-PAGE 
were excised and examined by mass spectrometry. The mass spectrometry results 
confirmed the presence of FANCD2, however it did not identify any strong candidates 
for further analysis (Table 1). 
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Figure 1. Immunoblot of FANCD2 immunoprecipitation 
PD20 patient cells containing empty vector or corrected with FANCD2-V5-
6xHis (D2-V5/6xHis) were grown to confluency and half the cells were treated with 
250 nM MMC for 16 hours. Cells were harvested following treatment and then lysed 
in NETN300 (20 mM Tris-HCl, 300 mM NaCl, 1 mM EDTA, 1 mM Na3O4V, 1 mM 
NaF, Roche protease inhibitor cocktail tablet). 1 mg of cellular extract was used for 
the immunoprecipitation which was supplemented with NETN100 to make a 1 mL 
sample. The samples were not subjected to the pre-clearing step. The commercially 
available V5 antibody was allowed to incubate with the sample overnight. 30 µg of 
cell extract was run in the first four lanes of a 3-8% Tris-Acetate gel as a control while 
5 µL of the 40 µL eluate was loaded into the last four lanes to probe the success of the 
IP. The SDS-PAGE was performed and followed by the immunoblotting protocol. The 
blot was probed with the FANCD2 (NB100-182, Novus Biologicals) antibody 
showing that the IP was able to enrich for FANCD2 as seen in lane seven and eight.  
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Figure 2. Coomassie stain of the FANCD2 immunoprecipitation 
35 µL of the 40 µL of eluate described in Figure 1 were resolved by SDS-
PAGE on a 3-8% Tris-Acetate gel then stained with the SimplyBlue SafeStain 
(LC6060, Invitrogen). The gel does not show any bands that are more prominent in the 
corrected line than in the hypomorphic line. Taken together with the results from the 
immunoblot it would suggest that the amount of differential protein present in the 
eluate is not above the threshold for detection using the coomassie reagent. A 1 mm 
wide vertical strip spanning the length of the gel was excised from lane two and lane 
four. The vertical strips were each separated into twelve 1 cm long pieces. These 1 cm 
long strips were cut into pieces no larger than 2 mm3. Samples underwent preparation 
for mass spectrometry as described in the materials and methods section and were 
submitted for analysis by mass spectrometry. The results from lane two were used to 
remove any nonspecific interactions that were pulled down with the beads appearing 
in lane four.  
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Table 1. Mass spectrometry results from PD20 FANCD2-V5/6xHis V5 IP 
These results were analyzed using ProteoIQ version 2.2. All results were 
subjected to a 5% false discovery rate validation. Proteins which were detected in the 
empty sample were removed from the proteins that were present in the V5 IP. Only 
ten proteins were validated using this method. The most prominent of the detected 
proteins was FANCD2 confirming the success of the IP. The other proteins that were 
detected registered very few spectral counts. Apart from the low rate of detection for 
these proteins several of the proteins are cytoplasmic or secreted and therefore are not 
likely to be involved or affected by the chromatin targeting of FANCD2. 
20 
 
 
 
  
Protein Function Empty spectra V5  spectra 
BBX HMG box transcription factor 0 1 
ENO2 Maintains and protects neurons 0 1 
FANCD2 Required for chromosomal stability 0 36 
FLJ59433 Translation elongation factor 0 1 
MYH1 Muscle contraction 0 1 
RPSAP58 Ribosome constituent 0 1 
S100-A14 Modulates p53 protein levels 0 1 
TRIM35 Possible Tumor Suppressor 0 2 
TUBA1A Cytoskeletal protein 0 2 
YBX1 Regulation of transcription 0 1 
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pLenti 6.2 FANCD2-V5 is Functionally Incorporated into the Cell  
Using the pLenti FANCD2-V5 vector to correct the cells shows a functional 
incorporation of the protein into the cellular machinery. The FANCD2-V5 undergoes 
ubiquitination following exposure to MMC (Figure 3) and is also localized to 
chromatin (Figure 4). To adequately correct the sensitivity to crosslinking agents 
FANCD2 must undergo monoubiquitination, chromatin localization, and discrete 
nuclear foci formation. Monoubiquitination demonstrates that the protein is at least 
interacting with the components of the core complex which ubiquitinate the protein. 
Chromatin localization places the protein in the context of DNA repair and in 
proximity with other DNA repair proteins. The ability to enrich activated chromatin 
associated FANCD2 allows for specific screening of interaction occurring in the 
context of an active DNA repair environment. The incorporated protein can be 
targeted by the commercial V5 antibody for enrichment, and should function as a 
useful platform to detect proteins that interact with activated FANCD2 in the context 
of DNA repair.    
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Figure 3. pLenti 6.2 FANCD2-V5 is efficiently ubiquitinated following exposure 
to crosslinking agents 
PD20 cells stably corrected with pLenti 6.2 FANCD2-V5 and a control line 
with stably incorporated pLenti 6.2 LacZ-V5 were grown to confluency and half of the 
cells were treated with 250 nM MMC for 16 hours. The cells were harvested and lysed 
in 2% SDS lysis buffer. The whole cell lysate was quantified using the BCA assay and 
samples were normalized to 30 µg than resolved by SDS-PAGE followed by 
immunoblotting with a V5 antibody. The immunoblot clearly shows an induction of 
monoubiquitinated FANCD2 following MMC treatment in the corrected line. This 
indicates that a sizeable portion of the FANCD2 that is expressed is functionally 
incorporated into the cell.  
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Figure 4. pLenti 6.2 FANCD2-V5 is localized to chromatin following exposure to 
crosslinking agents 
PD20 cells stably corrected with pLenti 6.2 FANCD2-V5 and a control line 
with stably incorporated pLenti 6.2 LacZ-V5 were grown to confluency and half of the 
cells were treated with 250 nM MMC for 16 hours. The cells were fractionated as 
described using the CSK buffer and NRB with micrococcal nuclease. The IP was 
performed using a V5 antibody with the chromatin associated fraction. 
Immunoblotting with FANCD2 shows the effect of enrichment by the fractionation 
and the immunoprecipitation. Lanes one through four show the soluable fraction 
which has a large proportion of the nonubiquitinated FANCD2. Lanes five through 
eight show the Chromatin associated fraction which as a clear enrichment for 
monoubiquitinated FANCD2. The nonubiquitinated form is able to associate with 
chromatin but at a much lower frequency possibly suggesting that monoubiquitination 
stabilizes the association. Lanes nine through twelve show that the IP is able to pull 
down the monoubiquitinated FANCD2 from the chromatin associated fraction. The 
H2A immunoblot demonstrates that the fractionation was specific for chromatin 
associated proteins. Histones are normally very tightly bound to DNA in the 
nucleosome, as expected H2A is absent from the soluble fraction but present in the 
chromatin associated fraction.   
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Fractionation Allows Isolation of FANCD2 Immune Complex Members from 
Endogenous Systems  
Isolating the chromatin associated portion of cells has shown to enrich 
activated FANCD2. However the fractionation method required large volumes of cells 
to generate large enough protein volumes to successfully IP from. Using transformed 
cells such as HeLa cells allows for the rapid generation of large volumes of high 
protein content cells. Using unmodified HeLa cells removes the option to pull down 
using the V5 epitope tag. The cells were fractionated and then underwent a FANCD2 
IP using an antibody against FANCD2 to enrich for FANCD2 immune complexes 
(Figure 5). The eluate was resolved by SDS-PAGE and stained to observe differential 
banding patterns which could be excised and submitted for analysis by mass 
spectrometry (Figure 6). The analysis revealed a number of functionally diverse 
candidates with varying detection strengths (Table 2). One of the difficulties with the 
endogenous system is the lack of specificity with the antibody used. The best available 
antibody for FANCD2 has multiple targets within the cell. The issue of nonspecific 
binding is exacerbated by the PIS control which also binds several proteins 
nonspecifically and may invalidate or mask interacting partners. While the HeLa 
system is able to identify several candidates the large amount of contaminants and 
nonspecific interactions in the data demonstrate the need for a more sensitive system 
to screen for interacting proteins.   
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Figure 5. Enrichment of FANCD2 from HeLa cells using FANCD2 
immunoprecipitation 
HeLa cells were grown to confluency and half were treated with 250 nM MMC 
for sixteen hours. The cells were fractionated using CSK buffer and NRB 
supplemented with micrococcal nuclease. 1 mg of the chromatin associated fraction 
was incubated with a FANCD2 antibody (NB100-182, Novus Biologicals) and pulled 
down using magnetic beads. The sample was also incubated with rabbit pre immune 
serum and magnetic beads as well as just the magnetic beads. Only the MMC treated 
The IPs are shown in the blot above as they were the only samples to be submitted to 
proteomic analysis. The immunoblot for FANCD2 (sc-20022, Santa Cruz) 
demonstrates that monoubiquitinated chromatin associated FANCD2 is present in the 
FANCD2 IP and is not pulled down nonspecifically by rabbit serum or the magnetic 
beads. The Immunoblot for H4 shows that the chromatin fractionation was successful. 
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Figure 6. Silver stain of FANCD2 immune complexes from HeLa cell chromatin 
fractions 
The remaining eluates from the IP in Figure 5 were resolved by SDS-PAGE 
then were stained with the mass spectrometry compatible silver stain kit. The gel 
contains the eluates of the bead pull down, the pre immune serum (PIS) pull down, 
and the FANCD2 pull down. The silver stain shows nine differentially staining 
regions in the gel between the PIS and FANCD2 pull downs. The nine regions 
indicated were excised from both lanes of the gel so that nonspecific interaction could 
be removed from the FANCD2 IP results. The bands were excised as fragments 
approximately 1 mm tall and 1 cm wide which were subsequently cut into 
approximately 1 mm3 cubes. The bands were distained were than subjected to the 
tryptic in gel digestion protocol. The six most prominent bands were submitted for 
mass spectrometry analysis. 
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Table 2. Abridged list of candidates identified from HeLa FANCD2 immune 
complexes 
These results were analyzed using ProteoIQ version 2.2. All results were 
subjected to a 5% false discovery rate validation. Proteins which were detected in the 
pre immune serum sample were removed from the proteins that were present in the 
FANCD2 IP. Using the Uniprot database Proteins that were detected that are found 
solely in the cytoplasm or extra cellular matrix of the cell were deemed as nonspecific 
because of the prefractionation before the IP which should have removed these 
interactions (Apweiler 2004). While working in a biosaftey cabinet and taking care to 
wipe all surfaces and instruments down with ultrapure water, it is still not possible to 
remove all environmental contamination. Several candidates were identified with this 
screen and not all positive results are displayed on this list. While several candidates 
have a significant number of spectral counts there are still many which have very few 
spectral counts. Candidates detected hail from a diverse functional background.  
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Protein Function Empty spectra V5  spectra 
ADAR RNA processing 0 5 
AZI1 Centrosomal protein 0 10 
CCAR1 Functions as a p53 coactivator 0 4 
CEP135 Involved in centriole biogenesis 0 4 
DHX29 ATP-binding RNA helicase 0 1 
DHX30 Interacts with DNA and SSBP1 0 20 
DHX9 Unwinds DNA and RNA 0 32 
FANCD2 Required for chromosomal stability 0 1 
LRPPRC Binds to poly(A) mRNAs 0 2 
MYBBP1A May activate or repress transcription 0 4 
NUP155 Component of nuclear pore complex 0 4 
NUP160 Involved in poly(A)+ RNA transport 0 2 
RBM6 Binds poly(G) RNA homopolymers 0 3 
SF3B1 Identified in spliceosome C complex 0 15 
SIN3B Acts as a transcriptional repressor 0 2 
SMC3 Required for chromosome cohesion 0 11 
STAG1 Component of cohesin complex 0 2 
SUGP2 May play a role in mRNA splicing 0 3 
TP63 transcriptional activator or repressor 0 3 
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Large Scale Enrichment of FANCD2 Immune Complexes from PD20 Patient 
Cells Identifies Several Interacting Candidates 
Previous work with the PD20 patient cells showed it was difficult to generate a 
large enough volume of the chromatin associated fraction to be able to enrich enough 
FANCD2 immune complexes to detect by silver stain. Large volumes of cells were 
cultured to perform fractionations and subsequent IPs on. The process was shown to 
enrich for chromatin associated monoubiquitinated FANCD2 (Figure 7). The silver 
stain showed sixteen detectable differential bands or regions between the IP samples 
which were analyzed by mass spectrometry (Figure 8). The mass spectrometry 
analysis revealed several candidate proteins, which have been broken down into six 
different groups which includes nucleosome remodeling, nuclear matrix, DNA repair, 
transcription regulation, chromosome maintenance, and a miscellaneous proteins 
group (Table 3-8). All of these tables were generated using ProteoIQ 2.2 analysis. All 
results were subjected to a 5% false discovery rate validation. Proteins that were 
detected that are found solely in the cytoplasm or extra cellular matrix of the cell were 
deemed as nonspecific because of the prefractionation before the IP which should 
have removed these interactions. Common contaminants of this method were detected 
and removed from candidate lists. Immune complex candidate proteins which were 
detected at an equal or higher rate in the sample lacking any V5 epitope were removed 
from the list and seen as a nonspecific interaction.   
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Figure 7. Enrichment of chromatin associated monoubiquitinated FANCD2 from 
PD20 patient cells 
PD20 empty and PD20 pLenti 6.2 FANCD2-V5 cells were each plated into 
sixty four 15 cm dishes and grown to confluency. All of the cells were treated with 
250 nM MMC for 16 hours and subsequently harvested. The cell pellets were 
fractionated using the CSK buffer to extract the soluable fraction (S) and ATM lysis 
buffer with benzonase to extract the chromatin associated fraction (C).  5.2 mg of the 
chromatin fraction was incubated with the V5 agarose beads to pull down FANCD2-
V5 immune complexes. The complexes were resolved by SDS-PAGE alongside 10 µg 
amounts of the cellular fractions to be used as controls. Immunoblotting with H3 
demonstrates the success of the fractionation and the FANCD2 immunoblot shows 
that FANCD2 was pulled down during the immunoprecipitation.  
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Figure 8. Silver stain of FANCD2 immune complexes from the PD20 cell 
chromatin fraction 
The remaining eluates from the IP in Figure 7 were resolved by SDS-PAGE 
than was stained with the mass spectrometry compatible silver stain kit. The gel shows 
two lanes of 10 µgs of the raw chromatin associated fraction in addition to the two V5 
IP eluates. The silver stain shows sixteen differentially staining regions in the gel 
between the PD20 empty and the PD20 FANCD2-V5 pull downs. The sixteen regions 
indicated were excised from both lanes of the gel so that nonspecific interaction could 
be removed from the FANCD2 IP results. The bands were excised as fragments 
approximately 1 mm tall and 1 cm wide which were subsequently cut into 
approximately 1 mm3 cubes. The bands were distained then subjected to the tryptic in 
gel digestion protocol. It should be noted that bands do not necessarily indicate the 
presence of a single discrete protein but are simply an abundance of protein above the 
threshold for detection. Several different protein co-migrating may contribute to the 
overall concentration of proteins possibly causing large smeared bands or regions with 
various detectable proteins. To reduce the problem of protein contamination work was 
performed in a biosaftey cabinet and care was taken to wipe all surfaces and 
instruments down with ultrapure water. The gel was also wrapped in saran wrap to 
prevent exposure to additional sources of contamination while it was being imaged, 
resulting in several observable distortions in the captured image of the gel.  
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Table 3. Nucleosome remodeling proteins in FANCD2-V5 immune complexes 
This table shows the candidates that were identified as nucleosome remodeling 
components. Numerous remodeling complex members were identified including the 
ASAP, BAF, FACT, and NuRD complexes. Also grouped in with this category are the 
histone proteins that were detected. It is difficult to identify the histone variants with 
the methods that were used in this screen so the variants represented in the table are 
reflection of the inherent uncertainty in different isoforms and postranslation 
modifications. More detailed analysis of histone members would require special 
proteomic techniques and parameters.  
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Protein Function Empty spectra V5  spectra 
ACIN1  Component of ASAP complex 
apoptosis and splicing complex  
1 3 
ANP32B  Cell cycling nucleasome chaperone  1 2 
BAG6  Chaperone involved in p53 activity 
and chromatin regulation H3K4me2  
0 2 
BRD3  Binds actlyated histones  0 1 
CDC73  Transcription regulation nucleosome 
remodeling complex H3 methylation  
0 5 
FBL  Histone methyl transferase 
H2AQ104me  
3 8 
H1F0  Histone H1  1 6 
H1FX  Histone H1  2 12 
H2AFJ  Histone H2A  1 13 
HIST1H1B  Histone H1  11 18 
HIST1H1C  Histone H1  18 73 
HIST1H1D  Histone H1  19 72 
HIST1H2AD  Histone H2A  1 12 
HIST1H2BK  Histone H2B  11 46 
HIST1H2BL  Histone H2B  13 46 
HIST1H2BN  Histone H2B  13 46 
HIST1H4H  Histone H4  6 19 
HIST2H3A  Histone H3  3 12 
KIF11  Component of large chromatin 
remodeling complex  
0 5 
NAT10  Able to actylate histones  0 12 
PHB2  HDAC recruitment  3 9 
RELA  Transcriptional regulator with 
DDX1 interacts with HDACs  
0 4 
SAP18  Nucleosome remodeling 
transcription  
3 7 
SMARCA4  Component of the BAF chromatin 
remodeling complex  
1 3 
SMARCA5  Helicase with nucleosome 
remodeling activity  
2 9 
SMARCB1  Chromatin remodeling  1 2 
SMARCC2  Chromatin remodeling for 
transcriptional activation/repression  
5 13 
SNF2L1  Nucleosome remodeling factor  1 5 
SUPT16H  Nucleosome reorganizer  1 14 
TRIM28  Recruits NuRD degrades p53  2 6 
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Table 4. Nuclear matrix proteins in FANCD2-V5 immune complexes 
 The nuclear matrix proteins identified largely fall into two groups relating to 
the nuclear envelope. The Lamin proteins were detected with high spectral counts but 
were also somewhat abundant in the control sample, though there is a clear increase in 
the number of spectra detected in the V5 sample. The other large group relates to the 
nuclear pore complex. Several nuclear pore proteins were identified in the screen and 
in past screens which has been previously published on (Boisvert 2013).  
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Protein Function Empty spectra V5  spectra 
FNBP3  Nuclear matrix  1 11 
LMNA  Nuclear membrane chromatin 
interacting  
38 101 
LMNB1  Nuclear membrane chromatin 
interacting  
25 51 
LMNB2  Nuclear membrane chromatin 
interacting  
23 52 
NUP107  Nuclear pore complex  0 5 
NUP188  Component of nuclear pore complex  0 2 
NUP93  Nuclear pore complex  5 11 
ODF2  Centrosome matrix required for 
localizing PLK1  
0 4 
RANBP2  E3 for SUMO of UBE2I component 
of nuclear pore complex required for 
export  
1 3 
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Table 5. DNA repair proteins in FANCD2-V5 immune complexes 
 DNA repair proteins identified in the screen are listed in the table above. While 
many of the proteins in this list are familiar to the FA pathway very few have a highly 
enrich spectral count in the V5 sample. While it is welcoming to see known FANCD2 
interacting proteins such as PCNA in the screen the strongest candidates identified in 
this group are VCP and SFPQ (Howlett 2009). These proteins may have a direct role 
in recruiting FANCD2 to sites of DNA damage. 
43 
 
 
  
Protein Function Empty spectra V5  spectra 
ASCC3  3'-5' DNA helicase involved in 
repair of alkylated DNA  
0 3 
DDX1  RNA clearance at DNA DSB  1 2 
ILF2  Stabilizes Ku70/Ku80  0 6 
PARP1  Base excision repair chromatin 
architecture required for PARP9 and 
53BP1 recruitment  
0 5 
PCNA  TLS  0 1 
PSMD1  Regulatory subunit of proteasome  0 3 
REV1  DNA repair  0 1 
SFPQ  Nucleotide binding may be involved 
in ss invasion and NHEJ  
1 9 
VCP  Recruited to stalled replication forks 
by SPRTN Recruits 53BP1  
1 13 
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Table 6. Transcription regulation proteins in FANCD2-V5 immune complexes 
A large number of proteins involved in the regulation of transcription were 
identified. These proteins are involved in both transcriptional activation and 
repression. With FANCD2 being implicated in transcriptional regulation it makes 
sense that it would interact with other transcription proteins (Park 2013). Many of the 
transcription factors identified hail from different functional backgrounds and do not 
readily divide into groups or complexes. 
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Protein Function Empty spectra V5  spectra 
AIMP2  Prevents p53 degredation  1 4 
ALYREF  mRNA transport THO complex 
component  
0 5 
ATAD2  Transcriptional coactivator of ESR1  1 3 
BTF3  Transcription  2 4 
CHCHD3  BAG1 repressor  0 1 
CSNK2A1  Cell signaling apoptosis 
transcription  
0 2 
CTNNB1  Negative regulator of chromosome 
cohesion  
0 15 
CTNND1  Catennin Wnt signaling  1 23 
DDX17  Helicase transcriptional regulation  10 34 
DDX3X  Transcription regulation  7 19 
DDX3Y  ATP dependant RNA helicase  5 14 
DDX5  Transcritiptional coactivator p53 
RUNX2  
15 45 
FHL2  Transcription regulation  0 6 
FLII  May be a transcriptional coactivator 
associated with hormone activated 
nuclear receptors  
1 9 
GAPDH  Carbohydrate degredation apoptosis  8 22 
HELZ2  Interacts with and coactivates 
PPARA and PPARG  
0 7 
HMGA1  Transcription regulation  0 2 
HMGN4  chromatin  0 1 
HNRPK  Interacts with p53 and p21 necessary 
for apoptosis  
1 2 
MYBBP1A  Transcriptional activator or 
repressor   
2 7 
NF2  Tumor supression  0 2 
PELP1  Coactivator of ER transcription 
corepressor of other hormone 
receptor transcription 
0 1 
RPB1  DNA dependant RNA polymerase 
component of RNA pol II  
0 7 
RPB2  Component of RNA pol II  2 10 
SAFB2  Binds matrix attachment region 
DNA estrogen receptor corepressor  
1 8 
SND1  Transcriptional and p100 coactivator 0 7 
SNW1  Transcriptional regulation and 
mRNA splicing p53 interacting  
2 5 
STAU1  DNA binding  1 3 
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Table 7. Chromosome maintenance proteins in FANCD2-V5 immune complexes 
 A large amount of proteins involved in chromosomal maintenance were 
identified in the screen. Multiple members of many groups were identified such as, 
centrosomal proteins, spindle proteins, replication initiation, cohesin, and condensin. 
Two of the MCM proteins identified in the screen have recently been shown to 
interact with FANCD2 (Lossaint 2013). Nearly all of the SMC proteins were 
identified in the screen which implicates FANCD2 interacting with cohesin, 
condensin, and the SMC5-SMC6 complex. The large number of centrosomal proteins 
detected in the screen also suggests an interaction between FANCD2 and the 
centrosome.  
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Protein Function Empty spectra V5  spectra 
AKAP8L  Chromatin condensation  1 6 
AURKB  Regulates chromosome alignment and 
stability as well as p53  
1 2 
AZI1  Centrosome  0 3 
CDC42  Apoptosis transcription Spindle  0 2 
CDK1  Regulates cell and centrosome cycling  2 7 
CEP135  Centrosomal protein centriole biogenesis  0 2 
CEP250  Important role in centrosome cohesion  0 3 
CKAP2  P53 dependant cell cycle regulator  0 3 
DYNC1LI1  Chromosome migration  0 2 
HAUS3  Centrosome integrity  1 2 
HAUS6  Spindle assembly interacts with PLK1  0 3 
LZTS2  Centrosome and Wnt signaling  0 1 
MCM5  DNA replication initiation  0 4 
MCM7  DNA replication initiation  0 4 
NCAPD2  Component of condensin I complex 0 6 
NDC80  Chromosome segregation  0 1 
NEK7  Centrosome spindle formation  0 2 
NUDCD2  Centrosome  0 1 
NUMA1  Involved in teathering centrosome to 
tubulin and spindle assembly  
12 31 
PCM1  Required for centrosome assembly and 
function interacts with CEP 250  
2 14 
PDS5  Regulator of sister chromatid cohesion 
during mitosis  
0 7 
PPP1CA  Chromatin structure  1 4 
PPP1CB  Regulates chromatin structure  0 3 
PPP2CB  Centrosome spindle  0 2 
PPP2R1A  Chromosome segregation  0 4 
SLC25A5  Chromosome segregation  1 26 
SMC1A  Involved in chromosome cohesion during 
cell cycle and damage  BRCA1 interactor  
0 19 
SMC2  Component of condensing complex  2 12 
SMC3  Required for chromosome cohesion  4 24 
SMC4  Component of condensin complex  1 12 
SMC6  Involved in dsDNA break HRR  0 5 
SPAG5  Required for normal chromosome 
segregation  
0 3 
TNKS1BP  Binds TNKS1 and TNKS2 colocalizes 
with chromosomes during mitosis  
0 3 
TOP1  Cuts one strand of DNA during 
replication and transcription  
1 9 
TOP2A  DNA topoisomerase 2 Makes DNA ds 
breaks required for mitotic segregation  
0 10 
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Table 8. Other candidate proteins in FANCD2-V5 immune complexes 
 The remaining proteins identified in the screen are mostly involved in nuclear 
import and ubiquitination. Several nuclear import proteins were identified however, it 
is unclear how these proteins interact with chromatin associated FANCD2. Ubiquitin 
was strongly enriched in the V5 sample however this ubiquitin could be a result of the 
monoubiquitination of FANCD2. With the experimental design the program has no 
way of determining the origin of ubiquitin in the sample and it is highly possible that 
the ubiquitin was cleaved off of FANCD2 or any of the other ubiquitinated proteins in 
the pathway. The analysis did not include searching for diglycine modifications 
indicating protein ubiquitination, so it is also unknown which proteins in the sample 
were ubiquitinated.   
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Protein Function Empty spectra V5  spectra 
IPO5  Nuclear import  0 3 
IPO9  Nuclear protein import  0 2 
KPNB1  Nuclear import  1 8 
TNPO1  Nuclear transport histones  1 8 
UBC Ubiquitin  9 82 
USP5  Degrades K48 ubiquitin linkages 
causes accumulation of p53  (Dayal 
2009) 
0 5 
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Validating Structural Maintenance of Chromosomes Candidates  
One of the strongest groups of candidates from the mass spectrometry screen 
was the structural maintenance of chromosomes proteins. SMC1A, SMC2, SMC3, 
SMC4 and SMC6 were detected in the large scale patient cell IP (Table 7). SMC3 was 
also detected in the endogenous IP system (Table 2). SMC1 and SMC3 are 
component of the cohesin complex along with STAG1 which was detected in the 
endogenous system (Table 2). The cohesin complex sister chromatids together which 
allows for the identification of sister chromatids (Rudra 2013). SMC2 and SMC4 are 
members of the condensing complex. CAPD2 is also a member of condensin which 
was detected in the PD20 patient screen (Table 7). The condensin complex is required 
for the proper condensation and segregation of chromosomes (Hirano 2012). The 
SMC5-SMC6 complex plays a role in DNA damage repair though this may be 
mediated through cohesin recruitment (Potts 2006). Components of these complexes 
were detected in the FANCD2 immune complexes by immunoblotting (Figure 9). The 
input in Figure 9 shows that there may be less SMC protein expressed in FANCD2 
hypomorphic cells following exposure to MMC, however expression of these proteins 
does not apper to be largely affected by FANCD2 or MMC (Figure 10). The dynamic 
of the interaction between FANCD2 and these proteins require further 
characterization. Because these proteins are involved in genomic stability it is possible 
that these proteins may have some overlapping functions with maintaining genomic 
stability. Using MAGI to query the cancer genome atlas shows that mutations in both 
the cohesin (5.96%) and condensin (5.42%) networks are common in cancer.   
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Figure 9. Structural maintenance of chromosomes proteins are present in 
FANCD2 immune complexes 
PD20 empty and PD20 pLenti 6.2 FANCD2-V5 cells were treated with 250 
nM MMC for 16 hours and subsequently harvested. The cell pellets were fractionated 
using the CSK buffer to extract the soluable fraction and ATM lysis buffer with 
benzonase to extract the chromatin associated fraction.  The chromatin fraction was 
incubated with the V5 agarose beads to pull down FANCD2-V5 immune complexes. 
The complexes were resolved by SDS-PAGE alongside 10 µg amounts of the 
chromatin fractions to be used as controls. Immunoblotting with the antibodies shown 
demonstrates that SMC1A, SMC4, SMC6, CAPD2 and CAPD3 are all present in 
FANCD2 immune complexes. These proteins represent cohesin, condensin-I, 
condensin-II, and the SMC5-SMC6 complex. 
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Figure 10. Structural maintenance of chromosomes proteins expression in PD20 
patient cells 
PD20 pLenti 6.2 LacZ-V5 and PD20 pLenti 6.2 FANCD2-V5 cells were 
treated with different doses of MMC (0nM, 50nM, 100nM, 250nM) for 16 hours and 
subsequently harvested. The cell pellets were lysed in 2% SDS lysis buffer to survey 
total levels of cellular expression.  30 µg of the lysate was loaded into a gel and then 
resolved by SDS-PAGE. Immunoblotting with the antibodies shown demonstrates that 
SMC1A, SMC4, SMC6, CAPD2 and CAPD3 are all present in both corrected cells 
and cells with hypomorphic FANCD2 expression. The profile also shows that the 
proteins are not grossly affected by the presence of MMC within the cell. This result 
excludes the possibility that the association is caused by increased expression of 
structural maintenance of chromosomes proteins within the cells following MMC 
exposure.   
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FANCD2 may Interact with Components of the SWI/SNF Complex 
Several SWI/SNF proteins were also identified in the mass spectrometry 
screen. SMARCA4, SMARCA5, SMARCB1, and SMARCC2 were all identified in 
the patient cells as members of FANCD2 immune complexes along with several other 
nucleosome remodeling proteins (Table 3). Among the other proteins discovered was 
SUPT16H which is known to interact with SWI/SNF proteins in complexes (Table 3). 
The SWI/SNF proteins are important for transcriptional regulation, determination of 
cellular fate, and tumor suppression (Lu 2013). Using MAGI to query the cancer 
genome atlas shows that mutations in the SWI/SNF network are very common in 
cancer (16.14%). Using inducible knockdown cells for SWI/SNF components it was 
demonstrated that FANCD2 expression is affected by knockdown of SWI/SNF 
components (Figure 11). The relationship that SWI/SNF proteins have with FANCD2 
may be more related to the canonical function of SWI/SNF proteins as chromatin 
remodelers and transcription regulators. It is possible that the interaction between 
FANCD2 and SWI/SNF proteins may be upstream of transcription or it may be 
involved in stabilizing FANCD2 protein levels.  
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Figure 11. SWI/SNF knockdown does not affect FANCD2 monoubiquitination 
The MCF10A cells used have a stably integrated cassette, which expresses a 
shRNA and GFP in the presence of doxycycline. The different cells have different 
knockdown targets, SMARCA2/BRM, SMARCA4/BRG1, and a scrambled shRNA 
which has no target. The cells were treated with 0.01 µg/mL of doxycycline for 72 
hours. During the final 24 hours of doxycycline treatment the cells were co-treated 
with 200 nM MMC. The cells were harvested and lysed with 2% SDS lysis buffer to 
extract the proteins from the cells. 30 µg of cell lysate was loaded into gels to be 
resolved by SDS-PAGE and subsequent immunoblotting. The cell were probed for 
GFP to assess if the shRNA was expressed, GFP expression in this case is a proxy for 
knockdown. The samples were also probed for FANCD2 to determine if knockdown 
of SWI/SNF component would impede the ubiquitination and therefore activation of 
the FA pathway. In the MCF10A cells used FANCD2 undergoes a normal 
ubiquitination response to MMC both with and without doxycycline mediated 
knockdown.  
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CHAPTER 4 
 
DISCUSSION 
 
Identifying FANCD2 Interacting Candidate Proteins 
 Using mass spectrometry to identify novel interacting partners has been a 
challenging and rewarding technique. There are many difficulties in working with a 
large low abundance protein, but the data generated from the mass spectrometry 
screen has shown many new interesting results. The technique was also able to detect 
some already known interactions such as PCNA (Table 5, Howlett 2009) and the 
MCM proteins (Table 7, Lossaint 2013). Developing a method which is able to pull 
down chromatin associated FANCD2 immune complexes to detect by mass 
spectrometry has opened the door for similar IP based experiments.  
The screen has identified several candidates from diverse functional groups 
which may indicate a larger functional role for FANCD2 and the FA-BRCA pathway. 
The numerous strong candidates identified by this method will require subsequent 
validation and characterization. This process has been started on several proteins 
however the large volume of data will require a systematic and methodical approach to 
utilize the data generated from the screen. The unbiased nature of the screen also does 
not discriminate against upstream or downstream proteins and does not occlude subtle 
events. Upstream events can be easily assayed by looking at FACND2 
monoubiquitination, chromatin localization, and nuclear foci formation, in response to 
interstrand crosslinking agents which are all well developed assays within the lab. 
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Genomic instability can be assayed through metaphase spreads to determine if a 
protein interaction is involved in promoting repair downstream of FANCD2. But the 
need for new methods may be most realized while investigating subtle effects, which 
may only be viewable during specific conditions, or may require more information 
from experiments than is currently recorded as data. As more is known about 
FANCD2 it is increasingly likely that newly identified interacting proteins may have a 
less visible effect on the cell, but that does not bar these new interactors from playing 
a profound or underappreciated role within the pathway.  
 
FANCD2 may Interact with the Structural Maintenance of Chromosomes 
Proteins 
 The mass spectrometry data show a strong likelihood that FANCD2 is 
involved with the structural maintenance of chromosomes proteins in some way. 
SMC3 is one of the few proteins that were detected in both the endogenous and patient 
systems (Table2, Table 7). Cohesin has been shown to be enriched at sites of stalled 
forks and the SMC proteins SMC1A, SMC3, SMC4, SMC5, and STAG2, have 
previously been detected as FANCD2 interacting candidates (Lossaint 2013). 
Knockdown for FA proteins and SMC proteins share a genomic instability and 
improper segregation phenotype (Nalepa 2014, Hirano 2012). With the connection to 
genomic instability the cohesin and condensin complexes as well as the SMC5-SMC6 
complex make excellent potential candidates for FANCD2 interactors. These proteins 
are also highly involved in chromatin architecture restructuring which may be a 
critical component to understanding how the FA-BRCA pathway becomes activated 
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upon damage detection. While the SMC proteins have been implicated in DNA repair 
the mechanism by which they act to repair DNA is currently unknown.  
 
FANCD2 may Interact with the SWI/SNF Proteins 
 The SWI/SNF proteins are known as both nucleosome remodelers and 
transcription factors (Lu 2013). As a known tumor suppressor and the large number of 
complex members identified (Table 3), the SWI/SNF proteins make strong candidates 
for evaluation. The affect that the SWI/SNF proteins have on FANCD2 protein levels 
may be of great importance and it may provide a mechanism by which the SWI/SNF 
cells act as tumor suppressors. It is important to continue to evaluate the relationship 
between FANCD2 and the SWI/SNF proteins. There are still many metrics for 
characterization to look at such as chromatin localization and FANCD2 nuclear foci 
formation. 
 
FANCD2 and Histones 
 Another notable interaction identified by this study is the interaction between 
FANCD2 and histones. Several histone variants were identified as the candidates 
however it is difficult to determine the strength of this interaction as the peptides also 
showed several spectral counts in the control sample, albeit at a lower frequency 
(Table 3). There are several possible reasons for this perceived interaction with 
histones, it may be an indirect interaction between nucleosome remodeling proteins 
that interact with FANCD2 or it may be an artifact of FANCD2 associating with 
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chromatin. However this does not preclude the possibility that FANCD2 may be 
directly interacting with histones. 
 The idea that FANCD2 may be interacting with histone is supported by the 
premise that FANCD2 acts as a histone chaperone (Sato 2012). This idea is further 
evidenced by the discovery of a possible histone binding domain within FANCD2 
(unpublished data). With the difference in some of the histone peptides detected in this 
experiment exceeding a fourfold change in some cases it is reasonable to believe that 
chromatin associated FANCD2 may have a direct interaction with histones. 
Enrichment is shown for Histone H1, Histone H2A, Histone H2B, Histone H3, and 
Histone H4 (Table 3). It is important to realize that DNA repair occurs within the 
context of chromatin and while detecting interactions with histones the abundance of 
posttranslational modifications and histone variants remains unknown and is not likely 
to be decoded with such a broad screening method.  
 The diversity and prevalence of histones and histone remodeling proteins 
within the data allude to the idea that FANCD2 may be involved in binding specific 
chromatin marks or in causing changes in the profile of chromatin modifications. The 
FA-BRCA pathway may be regulated by the histone code or alternatively may be 
actively involved in writing the histone code. With several of the proteins in the FA 
core complex being understudied it is possible that the FA core complex along with 
FANCD2 may have a role in recognizing and modifying structures in chromatin either 
is conjunction with or separate from the ability for the FA-BRCA pathway to promote 
repair of the highly genotoxic ICL lesions.  
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Conclusions 
 This project has demonstrated a successful method to enrich for chromatin 
associated active FANCD2 immune complexes, and has given large clues as to which 
proteins compose the activated FANCD2 immune complexes. While this data shows a 
dramatic increase in the information known about possible FANCD2 interacting 
proteins, the data still requires a great deal of investigation to be performed. The 
methods and data described here show the massive power associated with proteomics 
techniques. The discovery of several strong candidate interacting proteins as well as 
preliminary data to characterize the interaction should contribute to understanding the 
activity and regulation of FANCD2 and the larger FA-BRCA pathway function in a 
meaningful way. Hopefully the information generated in the screen can contribute to 
the improvement for healthcare options of FA patients and increase the understanding 
of how DNA repair is mediated within the cell.  
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